Distinct effects of NPY13-36, a specific NPY Y2 agonist, in a model of rodent endotoxemia on leukocyte subsets and cytokine levels

Annals of Anatomy

Volumn 193, Issue 6, 2011, Pages 486-493

  Stadler, Jan ^a   Le, Tina Phan ^b   Haas, Philipp ^a   Nave, Heike ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Clinic for Gynecology and Obstetrics   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Activated monocytes; Endotoxemia; Monocytes; NPY; Y2 receptor

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NEUROPEPTIDE Y [13-36]; TUMOR NECROSIS FACTOR ALPHA; ARGININE; BENZAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEUROPEPTIDE Y; NEUROPEPTIDE Y (13 36); NEUROPEPTIDE Y (13-36); NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; PEPTIDE FRAGMENT;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; ENDOTOXEMIA; FLUORESCENCE ACTIVATED CELL SORTING; GRANULOCYTE FUNCTION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPHOCYTE SUBPOPULATION; MALE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; RAT; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; IMMUNOLOGY; LEUKOCYTE; LEWIS RAT;

ANIMALIA; RATTUS; RODENTIA;

ANIMALS; ARGININE; BENZAZEPINES; CELLS, CULTURED; CYTOKINES; ENDOTOXEMIA; LEUKOCYTES; MALE; NEUROPEPTIDE Y; PEPTIDE FRAGMENTS; RATS; RATS, INBRED LEW; RECEPTORS, NEUROPEPTIDE Y;

EID: 81855201753     PISSN: 09409602     EISSN: 16180402     Source Type: Journal    
DOI: 10.1016/j.aanat.2011.10.009     Document Type: Article

References (44)

1. Arnalich F., Sánchez J.F., Martìnez M., Jiménez M., López J., Vázquez J.J., Hernan A. Changes in plasma concentrations of vasoactive neuropeptides in patients with sepsis and septic shock. Life Sci. 1995, 56:75-81.
2. Alves-Filho J.C., Freitas A., Spiller F., Souto F.O., Cunha F.Q. The role of neutrophils in severe sepsis. Shock 2008, 30:3-9.
3. Barnea A., Roberts J., Keller P., Word R.A. Interleukin-1beta induces expression of Neuropeptide Y in primary astrocyte cultures in a cytokine-spezific manner: induction in human but not rat astrocytes. Brain Res. 2001, 896:137-145.
4. Bauhofer A., Witte K., Celik I., Pummer S., Lemmer B., Lorenz W. Sickness behaviour, an animal equivalent to human quality of life, is improved in septic rats by G-CSF and antibiotic prophylaxis. Langenbeck Arch. Surg. 2001, 382:132-140.
5. Bedoui S., Kuhlmann S., Nave H., Drube J., Pabst R., von Horsten S. Differential effects of Neuropeptide Y (NPY) on leukocyte subsets in the blood: mobilization of B-1-like B-lymphocytes and activated monocytes. J. Neuroimmunol. 2001, 117:125-132.
6. Bracci-Laudiero L., Aloe L., Stenfors C., Tirassa P., Theodorsson E., Lundberg T. Nerve growth factor stimulates production of Neuropeptide Y in human lymphocytes. Neuroreport 1996, 7:485-488.
7. Castellheim A., Brekke O.L., Espevik T., Harboe M., Mollness T.E. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand. J. Immunol. 2009, 69:479-491.
8. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
9. Doods H., Gaida W., Wieland H.A., Dollinger H., Schnorrenberg G., Esser F., Engel W., Eberlein W., Rudolf K. BIIE0246: a selective and high affinity Neuropeptide Y Y(2) receptor antagonist. Eur. J. Pharmacol. 1999, 384:R3-R5.
10. Dotsch J., Christiansen H., Hanze J., Lampert F., Rascher W. Plasma Neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue Neuropeptide Y. Regul. Pept. 1998, 75:185-190.
11. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Hakanson R., Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibres. Regul. Pept. 1984, 8:225-235.
12. Erickson J.C., Clegg K.E., Palmiter R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking Neuropeptide Y. Nature 1996, 84:415-421.
13. Evequoz D., Waeber B., Corder R., Nussberger J., Gaillard R., Brunner H.R. Markedly reduced blood pressure responsiveness in endotoxemic rats; reversal by Neuropeptide Y. Life Sci. 1987, 41:2573-2580.
14. Felies M., von Horsten S., Pabst R., Nave H. Neuropeptide Y stabilizes body temperature and prevents hypotension in endotoxaemic rats. J. Physiol. 2004, 561:245-252.
15. Felies M., Poppendieck S., Nave H. Perioperative normothermia depends on intraoperative warming procedure, extent of the surgical intervention and age of the experimental animal. Life Sci. 2005, 77:3133-3140.
16. Gehlert D.R. Multiple receptors for the pancreatic polypeptide (PP-fold) family: physiological implications. Proc. Soc. Exp. Biol. Med. 1998, 218:7-22.
17. Grouzmann E., Alvares-Bolado G., Meyer C., Osterheld M.C., Burnier M., Brunner H.R., Waeber B. Localization of Neuropeptide Y and its C-terminal flanking peptide in human renal tissue. Peptides 1994, 15:1377-1382.
18. Haas P., Straub R.H., Bedoui S., Nave H. Peripheral but not central leptin treatment increases numbers of circulating NK cells, granulocytes and specific monocyte subpopulations in non-endotoxaemic lean and obese LEW-rats. Regul. Pept. 2008, 151:26-34.
19. Klonz A., Wonigeit K., Pabst R., Westermann J. The marginal blood pool of the rat contains not only granulocytes, but also lymphocytes, NK-cells and monocytes: a second intravascular compartment, its cellular composition, adhesion molecule expression and interaction with the peripheral blood pool. Scand. J. Immunol. 1996, 44:461-469.
20. Kopp J., Nanobashvili A., Kokaia Z., Lindvall O., Hokfelt T. Differential regulation of mRNAs for Neuropeptide Y and its receptor subtypes in widespread areas of the rat limbic system during kindling epileptogenesis. Mol. Brain Res. 1999, 72:17-29.
21. Labelle M., St-Pierre S., Savard R., Boulanger Y. Solution structure of neuropeptide tyrosin 13-36, a Y2 receptor agonist as determined by NMR. Eur. J. Biochem. 1997, 246:780-785.
22. Lecklin A., Lundell I., Paananen L., Wikberg J.E., Männistö P.T., Larhammar D. Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig. Br. J. Pharmacol. 2002, 135:2029-2037.
23. Macho P., Perez R., Huidobro-Toro J.P., Domenech R.J. Neuropeptide Y (NPY): a coronary vasoconstrictor and potentiator of catecholamine-induced coronary constriction. Eur. J. Pharmacol. 1989, 167:67-74.
24. Malmstrom R.E., Hokfelt T., Bjorkman J.A., Nihlen C., Bystrom M., Ekstrand A.J., Lundberg J.M. Characterization and molecular cloning of vascular Neuropeptide Y receptor subtypes in pig and dog. Regul. Pept. 1998, 75:55-70.
25. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. New Engl. J. Med. 2003, 348:1546-1554.
26. Medzhitov R., Janeway C. Innate immunity. New Engl. J. Med. 2000, 343:338-344.
27. Mitić K., Stanojević S., KuŠtrimović N., Vujić V., Dimitrijević M. Neuropeptide Y modulates functions of inflammatory cells in the rat: distinct role for Y1, Y2 and Y5 receptors. Peptides 2011, 32:1626-1633.
28. Morton K.D., McCloskey M.J., Potter E.K. Cardiorespiratory responses to intracerebroventricular injection of Neuropeptide Y in anaesthetised dogs. Regul. Pept. 1999, 81:81-88.
29. Nakajima M., Inui A., Asakawa A., Momose K., Ueno N., Teranishi A., Baba S., Kasuga M. Neuropeptide Y produces anxiety via Y2-type receptors. Peptides 1998, 19:359-363.
30. Nave H., von Horsten S., Helfritz F., Kuhlmann S., Ballof J., Drube J., Pabst R. Intravenous cannulation of the freely behaving rat: frequent blood sampling and volume-dependent effect on blood leukocyte counts. J. Exp. Anim. Sci. 1998, 39:67-77.
31. Nave H., Bedoui S., Moenter F., Steffens J., Felies M., Gebhardt T., Straub R.H., Pabst R., Dimitrijevic M., Stanojevic S., von Horsten S. Reduced tissue immigration of monocytes by Neuropeptide Y during endotoxaemia is associated with Y2 receptor activation. J. Neuroimmunol. 2004, 155:1-12.
32. Pinsky M.R., Vincent J.L., Deviere J., Alegre J., Kahn R.J., Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993, 103:565-575.
33. Polderman K.H., Girbes A.R. Drug intervention trials in sepsis: divergent results. Lancet 2004, 363:1721-1723.
34. Qureshi N.U., Dayao E.K., Shirali S., Zukowska-Grojec S., Hauser G.J. Endogenous neuropeptide Y mediates vasoconstriction during endotoxic and hemorrhagic shock. Regul. Pept. 1998, 75/76:215-220.
35. Schwarz H., Villiger P.M., von Kempis J., Lotz M. Neuropeptide Y is an inducible gene in the human immune system. J. Neuroimmunol. 1994, 51:53-61.
36. Silva A.P., Cavadas C., Grouzmann E. Neuropeptide Y and its receptors as potential therapeutical drug targets. Clin. Chim. Acta 2002, 326:3-25.
37. Smith-White M.A., Herzog H., Potter E.K. Role of Neuropeptide Y Y(2) receptors in modulation of cardiac parasympathetic neurotransmission. Regul. Pept. 2002, 103:105-111.
38. Straub R.H., Mayer M., Kreutz M., Leeb S., Schölmerich J., Falk W. Neurotransmitters of the sympathetic nerve terminal are powerful chemoattractants for monocytes. J. Leukocyte Biol. 2000, 67:553-558.
39. Struyt R.J., Netea M.G., Geijtenbeek T.B., Kullberg B.J., Dinarello C.A., van der Meer J.W. Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology 2003, 110:329-334.
40. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296:659-660.
41. van Leeuwen H.J., Van Der Tol M., Van Strijp J.A., Verhoef J., van Kessel K.P. The role of tumour necrosis factor in the kinetics of lipopolysaccharide-mediated neutrophil priming in whole blood. Clin. Exp. Immunol. 2005, 140:65-72.
42. von Hörsten S., Ballof J., Helfritz F., Nave H., Meyer D., Schmidt R.E., Stalp M., Klemm A., Tschernig T., Pabst R. Modulation of innate immune functions by intracerebroventricularly applied Neuropeptide Y: dose and time dependent effects. Life Sci. 1998, 63:909-922.
43. Wheway J., Herzog H., Mackay F. NPY and receptors in immune and inflammatory diseases. Curr. Top. Med. Chem. 2007, 7:1743-1752.
44. Zukowska-Grojec Z., Karwatowska-Prokopczuk E., Rose W., Rone J., Movafagh S., Ji H., Yeh Y., Chen W.T., Kleinman H.K., Grouzmann E., Grant D.S. Neuropeptide Y: a novel angiogenic from the sympathetic nerves and endothelium. Circ. Res. 1998, 83:187-195.